Methylation status of RASSF1A in patients with chronic myeloid leukemia

Leukemia Research

Volumn 33, Issue 8, 2009, Pages 1130-1132

  Avramouli, Antigoni ^a   Tsochas, Stefanos ^a   Mandala, Eudokia ^b   Katodritou, Eirini ^c   Ioannou, Maria ^a   Ritis, Konstantinos ^d   Speletas, Matthaios ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c Theagenion Anticancer Institute   (Greece)

^d DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Chronic myeloid leukemia; Methylation; RASSF1A

Indexed keywords

BCR ABL PROTEIN; IMATINIB; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ERYTHROLEUKEMIA CELL; FEMALE; GENE REARRANGEMENT; HUMAN; HUMAN CELL; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN METHYLATION; REMISSION; SIGNAL TRANSDUCTION;

DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, ABL; HEMATOPOIETIC STEM CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PROMOTER REGIONS, GENETIC; TRANSLOCATION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 67349086245     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.01.003     Document Type: Article

References (10)

1. Donninger H., Vos M.D., and Clark G.J. The RASSF1A tumor suppressor. J Cell Sci 120 (2007) 3163-3172
2. Johan M.F., Bowen D.T., Frew M.E., Goodeve A.C., and Reilly J.T. Aberrant methylation of the negative regulators RASSFIA SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 129 (2005) 60-65
3. Harada K., Toyooka S., Maitra A., Maruyama R., Toyooka K.O., Timmons C.F., et al. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene 21 (2002) 4345-4349
4. Kurzrock R., Kantarjian H.M., Druker B.J., and Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 138 (2003) 819-830
5. Oki Y., Kantarjian H.P., Gharibyan V., Jones D., O'Brien S., Verstovsek S., et al. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 109 (2007) 899-906
6. Rush L.J., and Plass C. Alterations of DNA methylation in hematologic malignancies. Cancer Lett 185 (2002) 1-12
7. Speletas M., Arvanitidi K., Tzoanopoulos D., Tsironidou V., Pardali E., Aggeli C., et al. Rapid mutational analysis of N-ras proto-oncogene in hematologic malignancies: a study of 77 Greek patients. Haematologica 86 (2001) 918-927
8. Yu J., Ni M., Xu J., Zhang H., Gao B., Gu J., et al. Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer 2 (2002) 29
9. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-DDCT) method. Methods 25 (2001) 402-408
10. Jost E., do O.N., Dahl E., Maintz C.E., Jousten P., Habets L., et al. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. Leukemia 21 (2007) 505-510